title: Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder.
abstract: OBJECTIVE
  This study aimed to evaluate the impact of tumour size on recurrence and progression in a population-based series of non-muscle-invasive bladder cancers.
  
  
  METHODS
  Clinical and pathological characteristics of patients with primary Ta/T1 bladder cancer were registered. The patients' tumours were categorized by size into five size groups (1-10, 11-20, 21-30, 31-40 and >40 mm) or three size groups (1-15, 16-30 and >30 mm).
  
  
  RESULTS
  The analysis included 768 evaluable patients with a mean follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Tumour size was associated with recurrence for tumours sized 21?30, 31?40 and >40 mm (p = 0.03, p < 0.001, p < 0.001, respectively) in the five size group and for tumours sized 16?30 and >30 mm (p = 0.003 and p < 0.001) in the three size group. Other factors affecting recurrence were T1 tumour category, multiplicity and surgery performed by residents (p < 0.001, p < 0.001, p = 0.002, respectively). Considering progression, there was no significant association with tumour size, and T1 category and local recurrence were the only significant risk factors (both p < 0.001).
  
  
  CONCLUSIONS
  Tumour size ?15 mm is associated with a lower risk of recurrence but not progression. Dividing tumour size into three size groups gives additional information compared with two size groups with cut-off at 30 mm.
authors.affiliation: Department of Urology, University Hospital, Linköping, Sweden. Georg.Jancke@lio.se
authors.forename: Georg
authors.initials: G
authors.lastname: Jancke
authors.forename: Johan
authors.initials: J
authors.lastname: Rosell
authors.forename: Staffan
authors.initials: S
authors.lastname: Jahnson
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D002277:Carcinoma / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002983:Clinical Competence; D018450:Disease Progression; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016016:Proportional Hazards Models; D047368:Tumor Burden; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine